Sling Therapeutics has secured $123 million in a series C financing round, according to a company announcement covered by Fierce Biotech. The proceeds are earmarked to carry its experimental oral medication for thyroid eye disease through a phase 3 clinical trial and, if successful, toward commercialization.
The therapy is designed as a direct competitor to Tepezza, an infused treatment for the same condition. Because Sling's candidate is taken orally, it could offer patients a less burdensome dosing option compared with intravenous infusions, though the source does not provide comparative efficacy or safety data.
The funding round represents a significant vote of confidence in the program, but the source notes no specific timeline for trial results or regulatory submission. All details in this article derive solely from the Fierce Biotech report.